Acesion Pharma announces Nature Medicine publication of clinical results in Atrial Fibrillation
AP30663 achieved proof of mechanism with first-in-class SK channel inhibition compound in atrial fibrillation – primary endpoint met:...
top of page
- Sep 26, 2023
- 5 min
Acesion Pharma Closes Oversubscribed €45M Series B Financing Round
Financing co-led by new investors Canaan and Alpha Wave, and with participation by the Global BioAccess Fund and existing investor Novo...
1,286 views
- May 15, 2023
- 4 min
Acesion Pharma Announces Positive Pre-Clinical Data for AP31969
Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial...
1,203 views
LATEST NEWS
bottom of page